NanoViricides Inc. (NNVC)

[changes_iv]

Hear-hear! NanoViricides, Inc. is not alone in this trek to the marketplace. Other companies, successful/experienced professionals in several fields, are involved in making sure Nanoviricides, Inc succeed in their efforts to bring their "shifting-paradigm of antiviral drugs" to their market. NanoViricides, Inc. doctors are doing what they do best, preparing the final candidates for the clinical trials (2014).

They have signed contracts/agreements (2012 - 2013), in preparation for Investigational New Drug (IND) submission to the FDA and human trials (2014), with:
1) Id3A, LLC as the architect for its lab and cGMP pilot production facility
2) MPH Engineering, LLC (“MPH”), to help with the overall project management and design engineering of its laboratory and cGMP pilot production facility
3) BASi for Toxicology and Safety studies (initiate GLP Safety/Toxicology studies)
4) Lovelace Respiratory Research Institute for IND-enabling Efficacy Studies on FluCide® and for Testing its Novel Drug Candidates against the Highly Lethal MERS Human Coronavirus
5) Public Health England to Test Nanoviricides Against H7N9, MERS

Nanoviricides, Inc. has been "laying down the tracks of the railway", path that will lead to the human trials (2014).